March 15th 2023
Delegates will analyze the most relevant and controversial issues within the field of ophthalmology at this year’s congress in Lisbon, Portugal, from March 24 to 25.
March 15th 2023
February 24th 2023
January 31st 2023
Oregon State University researchers take key step toward new treatment for hereditary blindnessJanuary 19th 2023
As a therapy for vision impairment resulting from inherited retinal degeneration, or IRD, the mRNA would instruct photoreceptor cells – faulty because of a genetic mutation – to manufacture the proteins needed for sight.
Study: Black and Hispanic patients treated for retinal detachment with surgery had worse vision results than white patientsJanuary 18th 2023
Researchers discovered that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.
2023: What awaits ophthalmology in the year aheadDecember 12th 2022
As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Risk of rhegmatogenous retinal detachment rises following cataract surgeryOctober 4th 2022
The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Acute retinal necrosis: Retinal detachment rates are unaffected by early treatment with intravitreal antivirals, vitrectomyOctober 2nd 2022
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
ASRS 2022 recap: Significant strides in DME, AMD discussed among retina specialistsJuly 18th 2022
The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, from July 13-16, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular edema dominated the conversation.
Investigating surgical approaches for progressive retinal detachments secondary to retinoschisisJuly 16th 2022
J. Fernando Arevalo, MD, PhD, investigated the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the two, and suggested that the combination approach may need further consideration.
Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuityJuly 14th 2022
Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.
Preventing retinal scarring with novel thermogel therapyJuly 10th 2022
A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.
New prognostic test emerges as strong predictor of metastasis of uveal melanomaMay 3rd 2022
Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
First pediatric patient dosed in LCA10 gene editing clinical trialApril 13th 2022
The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.
UCI study cites base editing as a durable one-time treatment for inherited retinal degenerationApril 12th 2022
According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.